Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003076 · ClinicalTrials.gov registry record · Phase 2
Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT00003076 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 152 participants.
The verdict
NCT00003076, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus.
Interventions
- DRUG eflornithine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 1995-10 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003076
The ClinicalTrials.gov registry entry for NCT00003076 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eflornithine is the first listed.
NCT00003076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003076 about?
NCT00003076 is a clinical study titled "Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus". RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectivenes...
What is the current status of trial NCT00003076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 1995-10. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00003076?
The interventions under investigation include: eflornithine (DRUG).
Who is sponsoring clinical trial NCT00003076?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.